BioTime Inc. (BTX)

0.92
AMEX : Health Technology
Prev Close 0.99
Day Low/High 0.90 / 0.97
52 Wk Low/High 0.66 / 2.61
Avg Volume 459.10K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 148.15M
EPS -0.40
P/E Ratio 4.60
Div & Yield N.A. (N.A)
BioTime Subsidiary LifeMap Sciences, Inc. Announces Financing Of Up To $3 Million From Share Exchange Agreement

BioTime Subsidiary LifeMap Sciences, Inc. Announces Financing Of Up To $3 Million From Share Exchange Agreement

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc.

BioTime Signs Agreements With Jade Therapeutics For Ophthalmological Drug Delivery Applications Of HyStem® Technology

BioTime Signs Agreements With Jade Therapeutics For Ophthalmological Drug Delivery Applications Of HyStem® Technology

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement ...

BioTime CEO Dr. Michael West To Present At The 2012 Agora Financial Investment Symposium

BioTime CEO Dr. Michael West To Present At The 2012 Agora Financial Investment Symposium

BioTime, Inc. (NYSE MKT:BTX) announced today that Chief Executive Officer Michael D.

BioTime CEO Dr. Michael West To Present At The Jefferies 2012 Global Healthcare Conference

BioTime CEO Dr. Michael West To Present At The Jefferies 2012 Global Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX) announced that its Chief Executive Officer, Michael D.

BioTime And Subsidiary LifeMap Sciences, Inc. Announce Release Of GeneCards® Version 3.08

BioTime And Subsidiary LifeMap Sciences, Inc. Announce Release Of GeneCards® Version 3.08

XenneX, a Division of LifeMap Sciences, Inc. and BioTime, Inc.

BioTime And Subsidiary LifeMap Sciences, Inc. Announce Agreement To Market MalaCards - A Database Of Human Diseases

BioTime And Subsidiary LifeMap Sciences, Inc. Announce Agreement To Market MalaCards - A Database Of Human Diseases

BioTime, Inc. (NYSE MKT: BTX) today announced that its subsidiary LifeMap Sciences, Inc.

BioTime Completes Merger Of XenneX, Inc. Into LifeMap Sciences, Inc.

BioTime Completes Merger Of XenneX, Inc. Into LifeMap Sciences, Inc.

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences, Inc.

BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update On Product Development

BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update On Product Development

BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.

BioTime And Its Subsidiary OrthoCyte Corporation Provides Update On Preclinical Development Of OTX-CP07

BioTime And Its Subsidiary OrthoCyte Corporation Provides Update On Preclinical Development Of OTX-CP07

BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime’s CEO Michael West, Ph.

BioTime’s Subsidiary OncoCyte Corporation Provides Update On PanC-DxTM, And Related Diagnostic Products

BioTime’s Subsidiary OncoCyte Corporation Provides Update On PanC-DxTM, And Related Diagnostic Products

BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.

BioTime’s Subsidiary Cell Cure Neurosciences, Ltd. Provides Update On OpRegen® Product Development

BioTime’s Subsidiary Cell Cure Neurosciences, Ltd. Provides Update On OpRegen® Product Development

BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S.

BioTime Provides Update On ReneviaTM Product Development

BioTime Provides Update On ReneviaTM Product Development

BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.

BioTime Demonstrates Efficient Method For The Manufacture Of Cartilage-Producing Cells From Human Embryonic Stem Cells

BioTime Demonstrates Efficient Method For The Manufacture Of Cartilage-Producing Cells From Human Embryonic Stem Cells

BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product ...

BioTime CEO Michael D. West To Present At The 8th GTC Stem Cell Summit 2012

BioTime CEO Michael D. West To Present At The 8th GTC Stem Cell Summit 2012

BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Board Of Directors Forms Science And Technology Committee

BioTime Board Of Directors Forms Science And Technology Committee

BioTime, Inc. (NYSE Amex:BTX) today announced that its Board of Directors has recently formed a Science and Technology Committee to oversee the development and commercialization of BioTime’s technology and...

BioTime’s Subsidiary OncoCyte Corporation Provides An Update On The Development Of The Novel Pan-Cancer Diagnostic Product PanC-DxTM

BioTime’s Subsidiary OncoCyte Corporation Provides An Update On The Development Of The Novel Pan-Cancer Diagnostic Product PanC-DxTM

BioTime, Inc. (NYSE Amex: BTX) and BioTime’s subsidiary OncoCyte Corporation today provided a progress report on the development of PanC-Dx TM , a novel diagnostic device developed at BioTime and OncoCyte to detect ...

BioTime CEO Michael D. West To Present At 2012 Maxim Group Growth Conference

BioTime CEO Michael D. West To Present At 2012 Maxim Group Growth Conference

BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer, Michael D.

BioTime Announces Fourth Quarter And Fiscal Year End 2011 Financial Results And Recent Corporate Accomplishments

BioTime Announces Fourth Quarter And Fiscal Year End 2011 Financial Results And Recent Corporate Accomplishments

Please replace the release with the following corrected version due to revisions to footnote 2 of the Condensed Consolidated Statement of Operations.

BioTime To Present At ROTH 24th Annual Growth Stock Conference

BioTime To Present At ROTH 24th Annual Growth Stock Conference

BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Financial Officer, Peter S.

BioTime CEO Michael D. West To Present At New York Stem Cell Summit

BioTime CEO Michael D. West To Present At New York Stem Cell Summit

BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.

BioTime Licenses Technology For Key Regulatory Gene Underlying Cancer And Stem Cell Reprogramming From The Wistar Institute

BioTime Licenses Technology For Key Regulatory Gene Underlying Cancer And Stem Cell Reprogramming From The Wistar Institute

BioTime, Inc. (NYSE Amex:BTX) today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100.

BioTime To Produce Stem Cells For Research In Muscle Disorders

BioTime To Produce Stem Cells For Research In Muscle Disorders

BioTime, Inc. (NYSE Amex: BTX) today announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases.

BioTime Signs Agreement With USCN Life Science To Source Antibody-Based Products

BioTime Signs Agreement With USCN Life Science To Source Antibody-Based Products

BioTime, Inc. (NYSE Amex: BTX) today announced agreements with USCN Life Science, Inc.

BioTime’s Subsidiary OncoCyte Corporation Announces Plans For The Novel Pan-Cancer Diagnostic Product PanC-DxTM

BioTime’s Subsidiary OncoCyte Corporation Announces Plans For The Novel Pan-Cancer Diagnostic Product PanC-DxTM

BioTime, Inc. (NYSE Amex: BTX) and BioTime’s subsidiary OncoCyte Corporation today announced plans for the development of PanC-Dx TM , a novel diagnostic device discovered at BioTime and OncoCyte to detect the...

BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies

BioTime Successfully Completes HyStem®-Rx Preclinical ISO 10993 Studies

BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the successful completion of ISO 10993 biocompatibility studies for...

BioTime, Inc. Appoints Andrew C. Von Eschenbach, M.D. To Its Board Of Directors

BioTime, Inc. Appoints Andrew C. Von Eschenbach, M.D. To Its Board Of Directors

BioTime, Inc. (NYSE Amex: BTX) and BioTime’s subsidiary, OncoCyte Corporation, today announced they have each appointed Dr.

BioTime Cell Information Now Available In GeneCards®

BioTime Cell Information Now Available In GeneCards®

BioTime, Inc. (NYSE Amex: BTX) and XenneX, Inc.

BioTime Announces Third Quarter 2011 Financial Results And Recent Corporate Accomplishments

BioTime Announces Third Quarter 2011 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September ...

BioTime CEO Michael D. West To Present Keynote Address At Translational Strategies For Tissue Engineering Conference

BioTime CEO Michael D. West To Present Keynote Address At Translational Strategies For Tissue Engineering Conference

BioTime, Inc. (NYSE Amex:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D.